BDSI files FDA NDA for BEMA Fentanyl
BioDelivery Sciences International has submitted its New Drug Application for BEMA Fentanyl, a treatment for breakthrough cancer pain, to the FDA. The application is based on positive results from clinical trials, including a Phase III efficacy trial that demonstrated significant pain reduction and low discontinuation rates.